# Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT00100711** · PHASE2 · TERMINATED · sponsor: **Pharmacyclics LLC.** · enrollment: 27 (—)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Motexafin Gadolinium

## Key facts

- **NCT ID:** NCT00100711
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-10
- **Primary completion:** 2010-02
- **Final completion:** —
- **Target enrollment:** 27 (—)
- **Last updated:** 2014-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00100711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00100711, "Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00100711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*